Indication

CD30+ Hematologic Malignancies

1 clinical trial

1 product

Clinical trial

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Status: , Estimated PCD: 2022-12-01

Product